EyePoint Pharmaceuticals (EYPT) Gains from Investment Securities: 2010-2024
Historic Gains from Investment Securities for EyePoint Pharmaceuticals (EYPT) over the last 15 years, with Dec 2024 value amounting to $17.5 million.
- EyePoint Pharmaceuticals' Gains from Investment Securities was N/A to -$95,000 in Q4 2019 from the same period last year, while for Dec 2019 it was $694,000, marking a year-over-year change of. This contributed to the annual value of $17.5 million for FY2024, which is 10281.07% up from last year.
- As of FY2024, EyePoint Pharmaceuticals' Gains from Investment Securities stood at $17.5 million, which was up 10,281.07% from $169,000 recorded in FY2023.
- In the past 5 years, EyePoint Pharmaceuticals' Gains from Investment Securities registered a high of $17.5 million during FY2024, and its lowest value of $90,000 during FY2020.
- Its 3-year average for Gains from Investment Securities is $6.0 million, with a median of $295,000 in 2022.
- As far as peak fluctuations go, EyePoint Pharmaceuticals' Gains from Investment Securities tumbled by 42.71% in 2023, and later spiked by 10,281.07% in 2024.
- EyePoint Pharmaceuticals' Gains from Investment Securities (Yearly) stood at $90,000 in 2020, then soared by 66.67% to $150,000 in 2021, then surged by 96.67% to $295,000 in 2022, then tumbled by 42.71% to $169,000 in 2023, then skyrocketed by 10,281.07% to $17.5 million in 2024.